271 related articles for article (PubMed ID: 7909866)
1. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.
Riethmüller G; Schneider-Gädicke E; Schlimok G; Schmiegel W; Raab R; Höffken K; Gruber R; Pichlmaier H; Hirche H; Pichlmayr R
Lancet; 1994 May; 343(8907):1177-83. PubMed ID: 7909866
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.
Riethmüller G; Holz E; Schlimok G; Schmiegel W; Raab R; Höffken K; Gruber R; Funke I; Pichlmaier H; Hirche H; Buggisch P; Witte J; Pichlmayr R
J Clin Oncol; 1998 May; 16(5):1788-94. PubMed ID: 9586892
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant and palliative immunotherapy of colorectal carcinoma].
Schlimok G
Praxis (Bern 1994); 1997 Sep; 86(39):1517-9. PubMed ID: 9411672
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
5. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
6. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
Tsavaris N; Gennatas K; Kosmas C; Skopelitis HM; Gouveris P; Dimitrakopoulos A; Zacharakis M; Kouraklis G; Vasiliou J; Felekouras E; Voros D; Zografos G; Balafouta M; Paraskevaidis M; Safioleas M; Fotiadis K; Papastratis G; Karatzas G; Papalambros E
Oncol Rep; 2004 Oct; 12(4):927-32. PubMed ID: 15375524
[TBL] [Abstract][Full Text] [Related]
7. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
8. Site and Stage of Colorectal Cancer Influence the Likelihood and Distribution of Disease Recurrence and Postrecurrence Survival: Data From the FACS Randomized Controlled Trial.
Pugh SA; Shinkins B; Fuller A; Mellor J; Mant D; Primrose JN
Ann Surg; 2016 Jun; 263(6):1143-7. PubMed ID: 26135689
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
10. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Mulder WM; Stern PL; Stukart MJ; de Windt E; Butzelaar RM; Meijer S; Adér HJ; Claessen AM; Vermorken JB; Meijer CJ; Wagstaff J; Scheper RJ; Bloemena E
Clin Cancer Res; 1997 Nov; 3(11):1923-30. PubMed ID: 9815581
[TBL] [Abstract][Full Text] [Related]
11. Edrecolomab (monoclonal antibody 17-1A).
Adkins JC; Spencer CM
Drugs; 1998 Oct; 56(4):619-26; discussion 627-8. PubMed ID: 9806108
[TBL] [Abstract][Full Text] [Related]
12. Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis.
Bentzen SM; Balslev I; Pedersen M; Teglbjaerg PS; Hanberg-Sørensen F; Bone J; Jacobsen NO; Sell A; Overgaard J; Bertelsen K
Br J Cancer; 1992 Jan; 65(1):102-7. PubMed ID: 1733432
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
14. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.
Hosch SB; Scheunemann P; Lüth M; Inndorf S; Stoecklein NH; Erbersdobler A; Rehders A; Gundlach M; Knoefel WT; Izbicki JR
J Gastrointest Surg; 2001; 5(6):673-9. PubMed ID: 12086907
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure.
Wunderlich M; Schiessel R; Rainer H; Rauhs R; Kovats E; Schemper M; Dittrich C; Micksche M; Sedlacek HH
Br J Surg; 1985 Sep; 72 Suppl():S107-10. PubMed ID: 3899250
[TBL] [Abstract][Full Text] [Related]
16. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
[TBL] [Abstract][Full Text] [Related]
17. [Meta-analysis of postoperative adjuvant chemotherapy for Dukes' B colorectal carcinoma].
Wan XB; Pan ZZ; Chen G; Li LR; Wan DS
Ai Zheng; 2005 May; 24(5):600-4. PubMed ID: 15890106
[TBL] [Abstract][Full Text] [Related]
18. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
19. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis.
Håkansson L; Adell G; Boeryd B; Sjögren F; Sjödahl R
Br J Cancer; 1997; 75(3):374-80. PubMed ID: 9020482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
